RG019

RG019 is an investigational liver-targeted RNA interference (RNAi) therapeutic being developed by Suzhou Xuanjing Biotechnology (also known as Rigerna Biotech) for the treatment of metabolic diseases. The candidate utilizes a dual-target approach, designed to simultaneously silence two distinct genetic targets involved in metabolic dysfunction. RG019 is delivered using Rigerna's proprietary liver-targeting platform, which likely employs ligand-mediated delivery (such as their R-GALA technology) to ensure precise uptake by hepatocytes. As of early development, the specific biological targets and the exact nature of the metabolic indications have not been publicly disclosed.